References:

Donehower LA. p53: guardian AND suppressor of longevity? Exp Gerontol.; 41(2006): 1212-7.

Finkel T, Serrano M, Blasco MAHu W, Feng Z, Ma L, et al. A single nucleotide polymorphism in the MDM gene disrupts the oscillation of p53 and MDM levels in cells. Cancer Res. ; 2007:67(7):2757-65.
Yu H, Huang YJ, Liu Z, et al. Effects of MDM promoter polymorphisms and p53 codon polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck. Mol Carcinog. ; 2007:46(8):751-8.
Agarwal ML, Taylor WR, Chernov MV, Chernova OB, Stark GR. The p53 network. J Biol Chem. ; 1998:273(1):1-4.
Oren M, Damalas A, Gottlieb T, et al. Regulation of p53: intricate loops and delicate balances. Biochem Pharmacol. ; 2002:64(5-6):865-71.
Ozeki C, Sawai Y, Shibata T, et al. Cancer susceptibility polymorphism of p53 at codon 72 affects phosphorylation and degradation of p53 protein. J Biol Chem. ; 2004:279(7):3191-8.
Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. ; 2004:119(5):591-602.
Kinyamu HK, Archer TK. Estrogen receptor-dependent proteasomal degradation of the glucocorticoid receptor is coupled to an increase in MDM2 protein expression. Mol Cell Biol. ; 2003:23(16):5867-81.
Phelps M, Darley M, Primrose JN, Blaydes JP. p53-independent activation of the HDM2-P2 promoter through multiple transcription factor response elements results in elevated HDM2 expression in estrogen receptor alpha-positive breast cancer cells. Cancer Res. ; 2003:63(10):2616-23.